Cetylpyridinium chloride
Based on 9 publication(s) in Google Scholar
Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-HBV capsid assembly inhibitor with an IC50 of 2.5 μM. Cetylpyridinium chloride is used in pesticides and various types of mouthwashes, and other personal care products.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.64%
- No. CAS: 123-03-5
- Fòrmula: C21H38ClN
- Peso molecular:339.99
-
Almacenamiento:
4°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cetylpyridinium chloride
More- Adv Sci (Weinh). 2026 Jun;13(36):e75157. [Abstract]
- Chem Eng J. 2025 Nov 12;525:170824.
- J Control Release. 2026 Apr 10:392:114649. [Abstract]
- Cell Death Dis. 2022 Mar 11;13(3):229. [Abstract]
- ACS Biomater Sci Eng. 2025 Sep 2. [Abstract]
- Inflammation. 2025 Feb 22. [Abstract]
- ACS Omega. 2025 Jul 30;10(31):34831-34843. [Abstract]
- ACS Omega. 2023 Jun 14;8(25):22603-22612. [Abstract]
- iScience. 2025 Nov 6.
Actividad biológica
Descripciòn
IC50 & Target
IC50: 2.5 μM (HBV capsid assembly)[1]
In Vitro
Cetylpyridinium chloride interacts with dimeric viral nucleocapsid protein (known as core protein or HBcAg) specifically. Compared with other HBV inhibitors, Cetylpyridinium chloride achieves significantly better reduction of HBV particle number in HepG2.2.15 cell line. Cetylpyridinium chloride inhibits capsid assembly and leads to reduced HBV biogenesis[1].
Cetylpyridinium chloride is a safe antimicrobial agent with broad-spectrum activity for preventing biofilm formation and gingivitis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (6-week old) injected with the plasmid [1]
-
Dosage:272 μg/kg/day
-
Administration:Intramuscular injection; daily; for 3 days
-
Result:Suppressed serum HBV DNA levels, decreased by 60% in day2 and 45% in day3 compared to the control.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 123-03-5
-
Appearance Solid
-
Peso molecular 339.99
-
Fòrmula C21H38ClN
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Cl-]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Hyperlipidemia Aggravates Alveolar Bone Loss via Periodontal Ligament Stem Cell Ferroptosis Through GSK3β Dependent Ubiquitin-Mediated NRF2 Degradation. [Abstract]2026 Jun;13(36):e75157. PMID: 41945797 -
-
J Control Release
Bioinspired nanomicelles with octopus-like adhesion for microenvironmental reprogramming in periodontitis. [Abstract]2026 Apr 10:392:114649. PMID: 41570864 -
Cell Death Dis
2022 Mar 11;13(3):229. PMID: 35277475 -
ACS Biomater Sci Eng
Electrospun Nanofibers Loaded with Concentrated Growth Factors and Nanohydroxyapatite for the Healing of Alveolar Bone in Tooth Extraction Wounds. [Abstract]2025 Sep 2. PMID: 40891613 -
Inflammation
4-Octyl Itaconate Attenuates Postmenopausal Osteoporosis by Inhibiting Ferroptosis and Enhancing Osteogenesis via the Nrf2 Pathway. [Abstract]2025 Feb 22. PMID: 39984770 -
ACS Omega
Urinary Bladder Matrix as a Guide Bone Regeneration Barrier Membrane for Inhibiting Cell Invasion and Promoting Bone Formation. [Abstract]2025 Jul 30;10(31):34831-34843. PMID: 40821524 -
ACS Omega
2023 Jun 14;8(25):22603-22612. PMID: 37387790 -
Solvente y solubilidad
In Vitro:
Ethanol : 100 mg/mL (294.13 mM; Need ultrasonic)
DMSO : 100 mg/mL (294.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (147.06 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (294.13 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureza y Documentación
-
Ficha de datos (271 KB)
-
SDS (625 KB)
- English - EN (625 KB)
- Français - FR (625 KB)
- Deutsch - DE (625 KB)
- Norwegian - NO (625 KB)
- Español - ES (625 KB)
- Swedish - SV (625 KB)
- Italian - IT (625 KB)
- Korean - KR (625 KB)
- Portuguese - PT (625 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Hyun Wook Seo, et al. Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly. Virus Res. 2019 Apr 2;263:102-111. [Content Brief]
[2]. Hiroto Imai, et al. Cetylpyridinium chloride at sublethal levels increases the susceptibility of rat thymic lymphocytes to oxidative stress. Chemosphere. 2017 Mar;170:118-123. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / Ethanol / DMSO | 1 mM | 2.9413 mL | 14.7063 mL | 29.4126 mL | 73.5316 mL |
| 5 mM | 0.5883 mL | 2.9413 mL | 5.8825 mL | 14.7063 mL | |
| 10 mM | 0.2941 mL | 1.4706 mL | 2.9413 mL | 7.3532 mL | |
| 15 mM | 0.1961 mL | 0.9804 mL | 1.9608 mL | 4.9021 mL | |
| 20 mM | 0.1471 mL | 0.7353 mL | 1.4706 mL | 3.6766 mL | |
| 25 mM | 0.1177 mL | 0.5883 mL | 1.1765 mL | 2.9413 mL | |
| 30 mM | 0.0980 mL | 0.4902 mL | 0.9804 mL | 2.4511 mL | |
| 40 mM | 0.0735 mL | 0.3677 mL | 0.7353 mL | 1.8383 mL | |
| 50 mM | 0.0588 mL | 0.2941 mL | 0.5883 mL | 1.4706 mL | |
| 60 mM | 0.0490 mL | 0.2451 mL | 0.4902 mL | 1.2255 mL | |
| 80 mM | 0.0368 mL | 0.1838 mL | 0.3677 mL | 0.9191 mL | |
| 100 mM | 0.0294 mL | 0.1471 mL | 0.2941 mL | 0.7353 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cetylpyridinium chloride Related Classifications
HY-B1464 Related Classifications
Powered by Bioz